- Full Time Employees
- 102
- Sector
- Technology services
- Industry
- Data processing services
- Address
- Seoul South Korea
- IPO Date
- Dec 26, 2019
- Business
- CJ Bioscience, Inc. is a South Korea-based biotechnology and bioinformatics company specializing in microbiome-based genomics, digital healthcare analytics, and precision wellness solutions. Operating as a dedicated red biotechnology subsidiary of CJ CheilJedang within the CJ Group, the company provides comprehensive bioinformatics tools, sequencing services, and diagnostic systems to academic institutions, clinical laboratories, pharmaceutical enterprises, and individual consumers globally. The company categorizes its primary business operations across specialized research services, bioinformatics platforms, and health diagnostics, offering: EzBioCloud, a proprietary cloud-based microbial taxonomic identification database and bioinformatics analytics platform utilized by researchers internationally; Next-Generation Sequencing (NGS) and multi-omics analytical services, including Microbiome Taxonomic Profiling (MTP), shotgun metagenomics, bacterial whole-genome sequencing, comparative genomics, and RNA sequencing; TrueBac ID, an automated genome-based bacterial identification and pathogen diagnostic system; Gut Inside, a clinical-grade gut microbiome profiling and Gut Microbiome Index (GMI) testing service distributed through hospitals and healthcare clinics; SMILE GUT, a direct-to-consumer gut microbiome home testing kit providing personalized lifestyle insights; and Ez-Mx, an artificial intelligence-driven data platform developed for microbial strain screening and biomarker discovery. Founded in 2009 as ChunLab, Inc. and headquartered in Seoul, South Korea, the company was acquired by CJ CheilJedang in 2021 and officially reorganized and renamed as CJ Bioscience, Inc. in January 2022. In major strategic developments, the company acquired 11 microbiome therapeutic candidates, patents, and intellectual property assets from UK-based 4D pharma plc in 2023 to expand its therapeutic pipeline. More recently, the company executed a strategic corporate reorganization to prioritize commercial business units and immediate cash-flow generation, refocusing resources on bioinformatics software services, health-functional foods, precision nutrition, and clinical diagnostic partnerships, such as a strategic healthcare cooperation agreement with Sun Medical Center, following the voluntary discontinuation of its Phase 1 immuno-oncology drug candidate CJRB-101.